Intellectual Property India Publishes Patent Application for Design, Synthesis And Biological Evaluation Of Coumarin Derivatives As Antimicrobial Agents

MUMBAI, India, Aug. 10 -- Intellectual Property India has published a patent application (202621079793 A) filed by Lakshmi Narain College Of Pharmacy on June 29, 2026, for Design, Synthesis And Biological Evaluation Of Coumarin Derivatives As Antimicrobial Agents.

Inventors include Dr. Govind Nayak; Dr. Priyanka Namdeo; and Ms. Karishma Gwala.

The application for the patent was published on July 31, 2026, under issue no. 31/2026.

Abstract: The present invention relates to a Coumarin-pyrazoline derivatives represented by 3-(5-substitutedphenyl)-4,5-dihydro-1H-pyrazol-3-yl-2H-chromen-2-one. The present invention provides Coumarin-pyrazoline derivatives synthesized through preparation of 3-acetyl coumarin, formation of substituted cinnamoyl coumarin intermediates and cyclization using hydrazine hydrate. The compound of Formula I are selected from, 3-(5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H- chromen-2-one (3A); 3-(5-(3-bromophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (3B); 3-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H- chromen-2-one (3C); (E)-3-(5-cinnamyl-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (3D); 3-(5-(4-hydroxy-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H- chromen-2-one (3E); 3-(5-(4-hydroxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (3F); 3-(5-(4-(dimethylamino)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)- 2H-chromen-2-one (3G); 3-(5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (3H). The compounds were characterized by FT-IR and 1H-NMR spectroscopy. Antimicrobial evaluation against Staphylococcus aureus and Escherichia coli demonstrated activity, with compounds 3-(5-(2-chlorophenyl)-4,5-dihydro- 1H-pyrazol-3-yl)-2H-chromen-2-one (3A); 3-(5-(3-bromophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (3B); and 3-(5-(3,4,5-trimethoxyphenyl)-4,5- dihydro-1H-pyrazol-3-yl)-2H-chromen-2-one (3C) showed the best antimicrobial activity among the synthesized compounds showing superior performance. The docking studies against protein target 4CV0 showed favorable interactions with TYR157 and THR195 residues.

Disclaimer: Curated by HT Syndication.